Arsonoliposomes for drug delivery applications

Clinical Lipidology

Volumn 4, Issue 5, 2009, Pages 663-675

  Antimisiaris, Sophia G ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Anticancer; Antiparasitic; Arsenic; Arsenolipid; Arsonolipid; Arsonoliposomes; Biodistribution; Drug carrier; Drug delivery; Liposomes

Indexed keywords

2,3 DIACYLOXYPROPYLARSONIC ACID; ANTILEISHMANIAL AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; ARSONIC ACID DERIVATIVE; ARSONOLIPOSOME; CYTOTOXIC AGENT; LIPOSOME; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID COMPOSITION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; TRYPANOSOMIASIS;

EID: 77649099187     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.09.42     Document Type: Review

References (71)

1. Drummond DC, Noble CO, Hayes ME et al.: Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J. Pharm. Sci. 97(11), 4696-4740 (2008).
2. Elbayoumi TA, Torchilin VP: Liposomes for targeted delivery of antithrombotic drugs. Exp. Opin. Drug Deliv. 5(11), 1185-1198 (2008).
3. Campbell RB, Ying B, Kuesters GM et al.: Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J. Pharm. Sci. 98(2), 411-429 (2009)
4. Torchilin V: Antibody-modified liposomes for cancer chemotherapy. Expert Opin. Drug Deliv. 5(9), 1003-1025 (2008).
5. Lammers T, Hennink WE, Storm G: Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer 99(3), 392-397 (2008).
6. Constantinides PP, Chaubal MV, Shorr R: Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev. 60(6), 757-767 (2008).
7. Banciu M, Schiffelers RM, Metselaar JM et al.: Utility of targeted glucocorticoids in cancer therapy. J. Liposome Res. 18(1), 47-57 (2008).
8. Antimisiaris SG, Fatouros D, Kallinteri P: Liposomes in drug delivery. In: Pharmaceutical Manufacturing Handbook, Section 5: New Dosage Forms. Gad E (Ed.). John Wiley and Sons, NY, USA, 443-533 (2008).
9. Patil RR, Guhagarkar SA, Devarajan PV: Engineered nanocarriers of doxorubicin: a current update. Crit. Rev. Ther. Drug Carrier Systems 25(1), 1-61 (2008).
10. Injac R, Strukelj B: Recent advances in protection against doxorubicin-induced toxicity. Tech. Cancer Res. Treat. 7(6), 497-516 (2008).
11. Torrado JJ, Espada R, Ballesteros MP et al.: Amphotericin B formulations and drug targeting. J. Pharm. Sci. 97(7), 2405-2425 (2008).
12. Bonacucina G, Cespi M, Misici-Falzi M et al.: Colloidal soft matter as drug delivery system. J. Pharm. Sci. 98(1), 1-42 (2009).
13. Allen TM, Cheng WWK, Hare JI et al.: Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med. Chem. 6(6), 513-523 (2006).
14. Fatouros D, Ioannou PV, Antimisiaris SG: Novel nanosized arsenic containing vesicles for drug delivery: arsonoliposomes. J. Nanosci. Nanotechnol. 6, 2618-2687 (2006).
15. Antimisiaris SG: Arsonoliposomes for drug delivery. J. Drug Deliv. Sci. Technol. 17(6), 377-388 (2007).
16. Bosch F, Rosich L: The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his nobel prize. Pharmacology 82(3), 171-179 (2008).
17. Liu J, Lu Y, Wu Q et al.: Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J. Pharmacol. Exper. Therapeutics 326(2), 363-368 (2008).
18. Dilda PJ, Hogg PJ: Arsenical-based cancer drugs. Cancer Treat. Rev. 33(6), 542-564 (2007).
19. Riethmiller S: From atoxyl to salvarsan: searching for the magic bullet. Chemotherapy 51(5), 234-242 (2005).
20. Soignet SL, Frankel SR, Douer D et al.: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19(18), 3852-3860 (2001).
21. Dombret H, Fenaux P, Soignet SL et al.: Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin. Hematol. 39(2 S1), 8-13 (2002).
22. Zheng P-Z, Wang K-K, Zhang Q-Y et al.: Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation apoptosis of promyelocytic leukemia. Proc. Natl Acad. Sci. USA 102(21), 7653-7658 (2005).
23. Chen Z, Chen GQ, Shen ZX et al.: Expanding the use of arsenic trioxide: leukemias and beyond. Semin. Hematol. 39(2 S1), 22-26 (2002).
24. Kallinteri P, Fatouros D, Klepetsanis P et al.: Arsenic trioxide liposomes. Encapsulation efficiency and in vitro stability. J. Liposome Res. 14(1-2), 27-38 (2004).
25. Chen H, MacDonald RC, Li S et al.: Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J. Am. Chem. Soc. 128(41), 13348-13349 (2006).
26. Timotheatou D, Ioannou PV, Scozzafava A et al.: Carbonic anhydrase interaction with lipothioasrenites: a novel class of isozymes I and II inhibitors. Met. Based Drugs 3, 263-268 (1996).
27. Tsivgoulis GM, Sotiropoulos DN, Ioannou PV: 1,2-dihydroxypropyl-3-arsonic acid: a key intermediate for arsonolipids. Phosphorus Sulfur Silicon Relat. Elem. 57, 189-193 (1991).
28. Tsivgoulis GM, Sotiropoulos DN, Ioannou PV: Rac-1,2-diacylo-xypropyl-3- arsonic acids: arsonolipid analogues of phosphonolipids. Phosphorus Sulfur Silicon Relat. Elem. 63, 329-334 (1991).
29. Serves SV, Sotiropoulos DN, Ioannou PV et al.: Synthesis of (R)- and (S)-1,2-diacyloxypropyl- 3-arsonic acids: optically active arsonolipids. Phosphorus Sulfur Silicon Relat. Elem. 71, 99-105 (1992).
30. Serves SV, Sotiropoulos DN, Ioannou PV et al.: One pot synthesis of arsonolipid via thioarsenite precursors. Phosphorus Sulfur Silicon Relat. Elem. 81, 181-190 (1993).
31. Tsivgoulis GM, Ioannou PV: A reinvestigation of the synthesis of arsonolipids (2,3-diacyloxypropylarsonic acids). Chem. Phys. Lipids 152(2), 113-121 (2008). n Describes the most recent (high-yield) method found for the synthesis of arsonolipids.
32. Devalla S, Feldmann J: Determination of lipid-soluble arsenic species in seaweed-eating sheep from Orkney. App. Organomet. Chem. 17, 906-912 (2003).
33. Dembitsky VM, Levitsky DO: Arsenolipids. Progr. Lipid Res. 43(5), 403-448 (2004).
34. Tran DN, Nagashima Y, Shiomi K: Watersoluble and lipid-soluble arsenic compounds in Japanese flying squid Todarodes pacificus. J. Agric. Food Chem. 55(8), 3196-3202 (2007).
35. Thomson D, Maher W, Foster S: Arsenic and selected elements in inter-tidal and estuarine marine algae, south-east coast, NSW, Australia. Appl. Organomet. Chem. 21(6), 396-411 (2007). (Pubitemid 46943659)
36. Rumpler A, Edmonds JS, Katsu M et al.: Arsenic-containing long-chain fatty acids in cod-liver oil: a result of biosynthetic infidelity? Angew. Chemie 47(14), 2665-2667 (2008).
37. Kigawa J, Minagawa Y, Kanamori Y et al.: Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer 82, 697-702 (1998).
38. Fatouros D, Gortzi O, Klepetsanis P et al.: Preparation and properties of arsonolipid containing liposomes. Chem. Phys. Lipids 109, 75-89 (2001).
39. Talsma H, Van Steenbergen MJ, Borchert JCH et al.: A novel technique for the one-step preparation of liposomes and nonionic surfactant vesicles without the use of organic solvents. Liposome formation in a continuous gas stream: the 'bubble' method. J. Pharm. Sciences 83(3), 276-280 (1994).
40. Koutsopoulos S, Fatouros DG, Ioannou PV, et al.: Thermal behavior of non-sonicated arsonolipid dispersions. Biophys. Chem. 121(2), 150-154 (2006).
41. Antimisiaris SG, Ioannou PV: Arsonoliposomes: Preparation and physicochemical characterization. In: Methods in Molecular Biology. Weissig V (Ed.). Springer /Humana Press, NJ, USA (2010) (In press).
42. Gortzi O, Papadimitriou E, Antimisiaris SG et al.: Cytotoxicity of arsonolipid containing liposomes towards cancer and normal cells in culture: effect of arsonolipid acyl chain length. Eur. J. Pharm. Sci. 18(2), 175-183 (2003).
43. Piperoudi S, Ioannou PV, Frederik P et al.: Arsonoliposomes: effect of lipid composition on their stability. J. Liposome Res. 15(3-4), 187-197 (2005). (Pubitemid 43062267)
44. Piperoudi S, Fatouros D, Ioannou PV et al.: Incorporation of PEG-lipids in arsonoliposomes can produce highly stable arsenic-containing vesicles of specific lipid composition. Chem. Phys. Lipids 139(2), 96-106 (2006).
45. Fatouros DG, Piperoudi S, Gortzi O et al.: Physical stability of sonicated arsonoliposomes: effect of calcium ions. J. Pharm. Sci. 94(1), 46-55 (2005).
46. Fatouros DG, Bouropoulos N, Ioannou PV et al.: Stability and aggregation studies of non-sonicated arsonolipid-containing vesicles. Cell Mol. Biol. Lett. 10(1), 173-183 (2005).
47. Antimisiaris SG, Ioannou PV, Loiseau PM: In vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in vivo distribution. J. Pharm. Pharmacol. 55(5), 647-652, (2003).
48. Antimisiaris SG, Klepetsanis P, Zachariou V et al.: In vivo distribution of arsenic after i.p. injection of arsonoliposomes in balb-c mice. Int. J. Pharm. 289(1-2), 151-158 (2005).
49. Zagana P, Klepetsanis P, Ioannou PV et al.: Trypanocidal activity of arsonoliposomes: effect of vesicle lipid composition. Biomed. Pharmacother. 61(8), 499-504 (2007).
50. Zagana P, Haikou M, Klepetsanis P et al.: In vivo distribution of arsonoliposomes: effect of vesicle lipid composition. Int. J. Pharm. 347(1-2), 86-92 (2008).
51. Kenworthy AK, Simon SA, McIntosh TJ: Structure and phase behavior of lipid suspensions containing phospholipids with covalently attached poly(ethylene glycol). Biophys. J. 68(5), 1903-1920 (1995).
52. Kenworthy AK, Hristova K, Needham D et al.: Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys. J. 68(5), 1921-1936 (1995).
53. Montesano G, Bartucci R, Belsito S et al.: Lipid membrane expansion and micelle formation by polymer-grafted lipids: scaling with polymer length studied by spin-label electron spin resonance. Biophys. J. 80(3), 1372-1383 (2001).
54. Garbuzenko O, Barenholz Y, Priev A: Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem. Phys. Lipids 135(2), 117-129 (2005).
55. Fatouros DG, Klepetsanis P, Ioannou PV et al.: The effect of pH on the electrophoretic behaviour of a new class of liposomes: arsonoliposomes. Int. J. Pharm. 288(1), 151-156 (2005).
56. Doak GO, Freedman LD: Organometallic Compounds of Arsenic, Antimony and Bismuth. Wiley, NY, USA, 26-27 (1970).
57. Strijkers GJ, Mulder WJM, Van Heeswijk RB et al.: Relaxivity of liposomal paramagnetic MRI contrast agents. MAGMA 18(4), 186-192 (2005).
58. Balana-Fouce R, Reguera RM, Cubria JC et al.: The pharmacology of leishmaniasis. Gen. Pharmacology 30(4), 435-443 (1998). (Pubitemid 28102818)
59. Date AA, Joshi MD, Patravale VB: Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Del. Rev. 59(6), 505-521 (2007).
60. Barratt G, Legrand P: Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis. Curr. Opin. Infectious Dis. 18(6), 527-530 (2005).
61. Owais M, Gupta CM: Targeted drug delivery to macrophages in parasitic infections. Curr. Drug Delivery 2(4), 311-318 (2005).
62. Kayser O, Kiderlen AF: Delivery strategies for antiparasitics. Exp. Opinion Invest. Drugs 12(2), 197-207 (2003).
63. Medda S, Jaisankar P, Manna RK et al.: Phospholipid microspheres: a novel delivery mode for targeting antileishmanial agent in experimental leishmaniasis. J. Drug Targ. 11(2), 123-128 (2003).
64. Gortzi O, Papadimitriou E, Kontoyannis CG et al.: Arsonoliposomes, a novel class of arsenic containing liposomes: effect of palmitoylarsonolipid containing liposomes on the viability of various cancer and normal cells in culture. Pharm. Research 19(1), 79-86 (2002). (Pubitemid 34075110)
65. Zagana P, Haikou M, Giannopoulou E et al.: Arsonoliposome interaction with cells in culture. Effect of pegylation and lipid composition. J. Mol. Nutr. Food Res. 53(5), 592-599 (2009).
66. Papadimitriou E, Antimisiaris SG: Interactions of PC/Chol and PS/Chol liposomes with human cells in vitro. J. Drug Target. 8(5), 335-351 (2000).
67. Haikou M, Zagana P, Ioannou PV et al.: Arsonoliposome interaction with thiols. Effect of pegylation and arsonolipid content on their integrity during incubation in the presence of glutathione. J. Nanosc. Nanotech. 6, 2974-2978 (2006).
68. Ghosh S, Strum JC, Sciorra VA et al.: Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid: Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13- acetate-stimulated Madin-Darby canine kidney cells. J. Biol. Chem. 271(14), 8472-8480 (1996).
69. Doxil (doxorubicin HCl liposome injection) www.doxil.com/
70. AmBisome (Amphotericin B liposome for injection) www.ambisome.com/
71. Trisenox® (Arsenic Trioxide) injection www.trisenox.com/